SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Mergers and acquisitions

Mergers and acquisitions

The pharmaceutical industry seems besieged on all sides, with declining R&D productivity, expiring patents on blockbuster products and relentless downward pricing pressure forcing companies to look closely at the bottom line. One affect of this onslaught has been an upsurge in the level of M&A activity as players within the industry consolidate to cut costs, expand research pipelines and lengthen geographic reach.

'Outperform' Perrigo better off without Mylan, says analyst report

30-Jun-2015 - The proposed Perrigo merger with Mylan would be of no benefit to either firm in the “highly competitive” OTC sector, according to financial analysts BMO.

‘Record-breaking’ 2015 will see surge in pharma acquisitions

25-Jun-2015 - Demand for CNS assets will help break records for pharma M&As in 2015, Neel Patel, VP of inVentiv Health consultancy Campbell Alliance, tells in-Pharmatechnologist.com. 

Dealing with activist shareholders: Allergan CEO shares advice at BIO

18-Jun-2015 - Ex-Allergan CEO David Pyott has spoken of his “total war” battling Valeant’s failed hostile takeover, and given advice to other pharmaceutical companies on how to deal with activist shareholders.

UPDATE - Mylan demands a straightforward answer to whether Teva will make a legally binding exchange offer

Teva to Mylan: We will accomplish our 'strong and serious' takeover proposal

08-Jun-2015 - Teva has refuted accusations of “meddling” with Mylan’s business in the latest chapter of what one analyst says is a far from friendly, if not hostile takeover attempt.

Mylan to Teva: 'Stop meddling in our affairs'

02-Jun-2015 - Teva has been accused of "playing games" with Mylan by acquiring a 1.35% stake in the generics firm weeks after having a $40bn (EUR36bn) takeover bid snubbed....

EC competition concerns will not stop $17bn Sigma-Aldrich deal, says Merck

28-May-2015 - Merck KGaA is confident it will close the $17bn acquisition of Sigma-Aldrich in mid-2015 despite competition concerns from the European Commission (EC).

Endo buys Par, Lupin enters Brazil... it's been a busy week in generics

19-May-2015 - Endo’s $8bn takeover of Par Pharmaceutical is expected to shake-up the generics sector, while Lupin is expanding its South American network – welcome to In-Pharmatechnologist’s M&A round-up.

Hospira approval puts Pfizer on track to close $17bn deal by year's end

18-May-2015 - Pfizer is set to close its $17bn (€15bn) acquisition by the end of the year after receiving the thumbs up from Hospira shareholders.

Siegfried set to buy custom synthesis and API units from BASF for $300m

07-May-2015 - BASF says it remains committed to the pharma industry despite plans to divest its custom synthesis business and around 100 APIs and intermediates to Siegfried Holding.

AMRI riding high on API acquisitions, expects more M&A to come

06-May-2015 - AMRI attributed a robust first quarter to its growing API business and recent acquisitions, and says to expect more M&A activity this year.

Mylan rejects $40bn bid, questions Teva’s credibility

28-Apr-2015 - Mylan has rejected an unsolicited bid by Teva and upped its offer for Perrigo, as the ongoing saga in the generics space continues.

Special from BPI Europe 2015

Eliminating fear culture can save operational costs and jobs, says Pfizer

23-Apr-2015 - Pfizer reduced costs 40% without cutting jobs at a facility in Sweden using an alternative approach to organisational and cultural behaviour, and hopes to do the same at its newly acquired Austrian...

Update

Teva bids $40bn for Mylan in proposed generics megamerger

21-Apr-2015 - A merger with Mylan would “transform the global generics space” says Teva, which has entered a $40bn bid as an alternative to the recently proposed Mylan-Perrigo deal.

Allergan axing a further 577 at Cali HQ, post-Actavis acquisition

21-Apr-2015 - Almost 600 staff at Allergan’s headquarters in Irvine, California, will be laid off in the Botox maker’s latest round of job cuts.

My oh Mylan! $29bn Perrigo deal would create 'unrivalled' manufacturing network

09-Apr-2015 - Mylan has bid $29bn (€27bn) to buy Perrigo in what the firm says will create a company with “unrivalled” manufacturing and supply chain capabilities across OTCs, generics and APIs.

Columbia Labs adds intra-vaginal ring tech and drug delivery pioneers

31-Mar-2015 - Columbia Laboratories has licensed a technology for delivering peptides using an intra-vaginal ring developed by MIT scientist Robert Langer.

No more waiting for the Sun: FTC approves $4bn Ranbaxy acquisition

30-Mar-2015 - Sun Pharmaceutical Industries has completed its $4bn (€3.7bn) acquisition of Ranbaxy after receiving the thumbs up from the US Federal Trade Commission (FTC).

AbbVie buys Pharmacyclics, bags Imbruvica blood cancer blockbuster

05-Mar-2015 - AbbVie is set to buy Californian small-molecule maker Pharmacyclics for $21bn (€19bn), cementing its haematology-oncology business.

Sun Pharma goes after opiates with deal to buy GSK’s Aus business

03-Mar-2015 - Indian giant Sun Pharma has bought GSK’s Australian Opiates business.

FTC requires Novartis to divest two potential cancer drugs to Array as part of GSK deal

24-Feb-2015 - In order to close Novartis’ $16bn purchase of GlaxoSmithKline’s portfolio of cancer treatments , the FTC (Federal Trade Commission) is requiring Novartis to divest all assets related to its potential BRAF and...

AMRI looks to close API facility in Wales as part of network realignment

12-Feb-2015 - AMRI has announced plans to close an API development and manufacturing plant in Wales, UK, after efforts to establish it as a conduit between the US and Europe were deemed...

Dispatches from BIO CEO 2015

Pfizer CEO slams US tax code, calls for more industry consolidation

11-Feb-2015 - In a wide-ranging interview that included his take on competition from Google and R&D spending, Pfizer CEO Ian Read offered a number of clues as to where his company is...

Pfizer 'comfortable' with Hospira's manufacturing network after quality review

09-Feb-2015 - Pfizer visited three troubled facilities in Hospira’s manufacturing network before entering a $17bn definitive merger agreement, the company says.

Vertellus buys antiretroviral API reagent plant from Dow

04-Feb-2015 - Specialty chemicals firm Vertellus will continue to supply antiretroviral drugmakers sodium borohydride following its takeover of a Dow plant in Washington State.

UPDATE

Novartis: New cost-saving unit will not target manufacturing network

29-Jan-2015 - Novartis has divested, restructured, or mothballed 24 manufacturing plants since 2010 but says its new NBS cost-saving business will not focus on streamlining and consolidating sites.

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...